NEW YORK, April 2, 2025 /PRNewswire/ — Medivis Inc., a pioneer in surgical intelligence, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its groundbreaking Spine Navigation platform. This milestone marks a significant advancement in surgical technology, utilizing AR and AI to empower surgeons with holographic navigation across open and minimally invasive spine procedures. Alongside the FDA clearance, Medivis is announcing the commercial launch of Spine Navigation, making it available to hospitals and ambulatory surgical centers nationwide.
“Surgery is entering a new era of advanced computing that enhances precision, speed, and efficiency in the operating room. This is a pivotal moment in medicine, and we are thrilled to deliver a solution that will elevate patient care to new heights,” said Dr. Christopher Morley, President of Medivis.
“At Medivis, we envision a future where surgical navigation transcends boundaries by integrating imaging data with the operative field. With our recent FDA clearance for Spine Navigation, we are thrilled to equip surgeons with breakthrough technology to visually transform spine surgery and empower them with intuitive image guidance,” added Dr. Osamah Choudhry, CEO of Medivis.
Medivis’ Spine Navigation platform is applicable across neurosurgery and orthopedic surgery. Its key strengths include:
Spine Navigation is the latest addition to the company’s portfolio of AI-powered surgical solutions, which are designed to transform the operating room and enhance surgical precision across a range of specialties.
About Medivis
Medivis is a leading surgical intelligence company dedicated to pioneering the future of surgical navigation with artificial intelligence and augmented reality. To learn more, visit www.medivis.com.
Contact: brooke@medivis.com
SOURCE Medivis
Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025CORAL…
More than 50% of men now face erectile dysfunction after the age of 40. In…
BEIJING, April 27, 2025 (GLOBE NEWSWIRE) -- On April 25, 2025, the 66th (Spring 2025)…
After six months of research on the ingredients and thousands of feedback from real consumers,…
Data Presented at the AUA Meeting Reflect Longest-Term Data among FIT InterventionsSOUTH SAN FRANCISCO, Calif.,…
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003…